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MaBACKGROUND The number of alternatives to intra-aortic balloon counterpulsation in the treatment of anticipated
and established acute circulatory failure is growing. Despite the clinical importance and signiﬁcant cost of short-term
mechanical circulatory support (MCS) devices, the state of their present use has not been analyzed on a national scale.
OBJECTIVES The purpose of this study was to characterize the demographics, treatment practices, survival rates, and
cost of short-term MCS.
METHODS In this serial cross-sectional study, we analyzed all adult patients receiving short-term MCS in the United
States from 2004 to 2011 by using the Nationwide Inpatient Sample from the Healthcare Cost and Utilization Project.
RESULTS From 2007 to 2011, use of percutaneous devices for short-term MCS increased by 1,511% compared with a
101% increase in nonpercutaneous devices. Mortality rates declined over this period (p for trend ¼ 0.027) from 41.1% in
2004 to 2007 to 33.4% in 2008 to 2011. A similar trend was observed for the subset of patients with cardiogenic shock,
decreasing from 51.6% to 43.1% (p for trend ¼ 0.012). Hospital costs also declined over this period (p for trend ¼ 0.011).
Multivariable analysis revealed balloon pumps (odds ratio [OR]: 2.00; 95% conﬁdence interval [CI]: 1.58 to 2.52),
coagulopathy (OR: 2.35; 95% CI: 1.88 to 2.94), and cardiopulmonary resuscitation (OR: 3.50; 95% CI: 2.20 to 5.57)
before short-term MCS were among the most signiﬁcant predictors of mortality.
CONCLUSIONS Use of short-term MCS in the United States has increased rapidly, whereas rates of in-hospital
mortality have decreased. These changes have taken place in the context of declining hospital costs associated
with short-term MCS. (J Am Coll Cardiol 2014;64:1407–15) © 2014 by the American College of Cardiology Foundation.A cute circulatory collapse is a broad termreferring to failure of the pumping mecha-nism of the heart and an inability to maintain
adequate organ perfusion. The most common situa-
tion in which it is encountered is cardiogenic shock.
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ABBR EV I A T I ON S
AND ACRONYMS
AMI = acute myocardial
infarction
CAD = coronary artery disease
and other heart disease
CCS = Clinical
Classiﬁcation Software
CHF = congestive heart failure
ECMO = extracorporeal
membrane oxygenation
HCUP = Healthcare Cost and
Utilization Project
HVD = heart valve disorder
IABP = intra-aortic balloon
pump
LVAD = left ventricular
assist device
MCS = mechanical
circulatory support
PCI = percutaneous
coronary intervention
PCPS = percutaneous
cardiopulmonary support
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1408bias toward supporting patients perceived as
eligible for transplant or left ventricular
assist device (LVAD) implantation (either
bridge or destination therapy). More
recently, the availability of rapidly deploy-
able percutaneous MCS has led to a paradigm
shift in the ﬁeld that is characterized by
growing use of these devices in an anticipa-
tory or prophylactic fashion that was previ-
ously uncommon. Although the intra-aortic
balloon pump (IABP) is not a true circulatory
support device because it does not contribute
directly to cardiac output, it was the only
rapidly deployable support device available
for decades. Reliable circulatory devices
including the Thoratec PVAD (Thoratec Cor-
poration, Pleasanton, California), AB5000
and BVS 5000 (both Abiomed, Inc., Danvers,
Massachusetts), and various centrifugal
pumps usually require a median sternotomy.
Venoarterial extracorporeal membrane
oxygenation (ECMO) delivered through pe-
ripheral cannulation with a centrifugal pumpdriver is another option but has always been re-
served for emergency near-arrest situations. The
morbidity and mortality associated with these de-
vices are signiﬁcant and restricted their use to po-
tential transplant candidates.SEE PAGE 1416The Impella 2.5 (Abiomed, Inc., Danvers, Massa-
chusetts) and TandemHeart (CardiacAssist, Inc.,
Pittsburgh, Pennsylvania) are percutaneous MCS
devices that can be deployed in the catheterization
laboratory. The CentriMag (Thoratec Corporation,
Pleasanton, California) and the Impella 5.0/CP have
greatly increased ease of cannulation and device
placement. These developments, among others, have
theoretically made possible early deployment of
short-term MCS before the downward spiral and
inﬂammatory cascade associated with circulatory
collapse can develop. Irrespective of surgical or
percutaneous deployment, all temporary MCS devices
share similar functional characteristics in terms of
augmentation of cardiac output in liters per minute.
In U.S. and European guidelines for acute heart
failure, the mainstays of therapy remain intravascular
volume control, inotropes, and IABP (1,2). The com-
bination of revascularization, antithrombotic ther-
apy, and intensive care management has only
modestly affected the mortality of cardiogenic
shock in the last decade (3,4). Despite a paucity of
randomized trials, recent guidelines have recom-
mended the use of short-term MCS for profoundhemodynamic compromise (1,5); these recommenda-
tions reﬂect the growing impact of short-term MCS on
clinical practice and the lack of viable alternatives.
Unlike the Interagency Registry for Mechanically
Assisted Circulatory Support (INTERMACS) and Ex-
tracorporeal Life Support Organization (ELSO) regis-
tries, which track outcomes and adverse events in
patients receiving long-term MCS and ECMO, no
such registry exists for short-term MCS. To begin
addressing the existing deﬁcit of information on
patients receiving short-term MCS, we examined
national trends in utilization.
METHODS
DATA SOURCE. The Nationwide Inpatient Sample,
Healthcare Cost and Utilization Project (HCUP), under
the auspices of the Agency for Healthcare Research
and Quality (6), is the largest database of all-payer
inpatient hospital stays in the United States. It ap-
proximates a 20% stratiﬁed sample of all nonfederal
hospitals. All discharges from sampled hospitals are
included, thus enabling the generation of national
estimates. This study was deemed exempt by Yale
University’s Institutional Review Board.
INCLUSION CRITERIA. We included all adults $18
years old who were receiving short-termMCS between
2004 and 2011. Short-term MCS was deﬁned by the
International Classiﬁcation of Diseases-ninth revision-
Clinical Modiﬁcation (ICD-9-CM) codes for percuta-
neous (37.68) or nonpercutaneous (37.60, 37.62, and
37.65) MCS in any procedure position (Online Figure 1).
Nonpercutaneous devices included the Thoratec
PVAD, AB5000, BVS 5000, and CentriMag. Percuta-
neous devices included the TandemHeart and Impella
devices. IABP (37.61), ECMO (39.65), and percutaneous
cardiopulmonary support (PCPS) (39.66) were ex-
cluded from our deﬁnition of short-term MCS. Perma-
nent devices (37.52 and 37.66) included the HeartMate
XVE and HeartMate II (Thoratec Corporation). Earlier
years were not analyzed because ICD-9-CM codes do
not distinguish short-term from permanent MCS
devices before 2004.
DEMOGRAPHICS. Elixhauser comorbidities were ge-
nerated from ICD-9-CM diagnosis codes using the
HCUP Comorbidity Software (7). The sum of comor-
bidities for each record was reclassiﬁed as 0, 1, 2,
or $3. Comorbidities present in $5% of all patients
were reported.
HOSPITAL COURSE. We deﬁned the indication for a
hospital stay as the diagnosis listed in the primary
position and categorized each using HCUP Clinical
Classiﬁcation Software (CCS). Level 3 CCS diagnoses
constituting $5% of all indications for hospital stays
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FIGURE 1 Use of MCS Devices Between 2004 and 2011
Use of percutaneous devices, permanent devices, extracorporeal
membrane oxygenation (ECMO), and percutaneous cardiopul-
monary support (PCPS) has grown considerably, whereas rela-
tively little change in use has been observed for intra-aortic
balloon pump (IABP) and nonpercutaneous devices. MCS ¼
mechanical support device.
TABLE 1 Sample Patient and Hospital Demographics
2004–2007 2008–2011
Female 33.5 28.6
Age, yrs
18–34 5.7 4.7
35–49 15.8 12.5
50–64 38.9 35.7
65–79 33.4 35.3
$80 6.2 11.9
Race
White 75.6 70.4
Black 8.8 11.9
Other 15.6 17.7
Primary payer
Medicare 42.5 50.2
Medicaid 9.4 9.8
Private insurance 39.3 33.3
Other* 8.8 6.7
Median household income
0–25th percentile 21.3 27.8
26th–50th percentile 23.8 23.5
51st–75th percentile 24.3 23.1
76th–100th percentile 30.7 23.7
Teaching hospital 79.1 77.3
Urban location 99.0 96.0
Large hospital by bed size 76.6 80.8
Region
Northeast 31.8 24.4
Midwest 22.9 23.7
South 27.9 29.7
West 17.4 22.2
Values are %. *Includes self-pay, no charge, or other.
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1409were classiﬁed as discrete categories, whereas
remaining diagnoses were merged into a single cate-
gory of other miscellaneous indications. Mortality
rates were deﬁned as the percentage of patients who
died before discharge.
COST ANALYSIS. We used HCUP cost-to-charge ra-
tios for each hospital, based on information from the
Centers for Medicare and Medicaid Services, to adjust
the total charges for each patient and to estimate
costs. When a hospital-speciﬁc cost-to-charge ratio
was not available, we used the corresponding state-
level ratio. These estimates were then adjusted for
inﬂation by using the Consumer Price Index Inpatient
Hospital Services inﬂation multiplier (8), with 2011 as
the base year. Hospital costs incurred by permanent
device implantation or heart transplantation were
included in all calculations.
STATISTICAL ANALYSIS. An abrupt change in utili-
zation pattern was observed in 2008. Based on this
ﬁnding, weighted means for demographic and hos-
pital course characteristics were calculated and
presented as illustrative data for 2004 to 2007 and
for 2008 to 2011 in aggregate. To test for linear and
curvilinear trends in disease characteristics and
outcomes over time, we adopted a method of
variance-weighted regression (9,10). This method-
ology incorporates the standard errors associated
with the estimates of each year but does not as-
sume homogeneity of variance. The threshold for
including yearly estimates was a relative standard
error <30%.
Data from 2005 were excluded from the mortality
trend analysis because 2 of 53 hospitals caused a
signiﬁcant downward distortion of overall mortality
in a manner inconsistent with all other years exam-
ined. Trend analyses for hospital costs and length of
stay were performed before and after removing the
top 1% of values, with similar results (latter data not
shown).
Multivariable logistic and linear regression was
used to calculate the association among independent
variables, in-hospital mortality, and the total cost of
hospital stay. Hierarchical models were used to ac-
count for clustering of cases by hospital. Length of
stay and total cost of hospital stay were both log-
transformed to achieve less positively skewed distri-
butions. Elixhauser comorbidities affecting $5% of
patients were included as independent variables if
they were signiﬁcantly associated with outcomes on
bivariate analysis. The signiﬁcance level was set a
priori at a p value #0.05. Statistical analyses were
performed using SPSS version 21.0 (IBM Corporation,
Armonk, New York) (Online Methods).
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1410RESULTS
UTILIZATION. An estimated 11,887 patients received
short-term MCS between 2004 and 2011. Whereas use
of temporary nonpercutaneous devices increased
101% from 2007 to 2011, percutaneous device use
increased by 1,511%. Indeed, percutaneous devices
exhibited the fastest growth of all forms of MCS in
this period (Figure 1, Online Table 2).
DEMOGRAPHICS. Most patient-related and hospital
characteristics remained similar over time (Table 1).Trends in Hospital Course and Disease Characteristics
2004–2007 2008–2011 p Value
dmission 32.5 24.7 0.001
type*
ansfer — 61.9 —
from an acute care hospital — 34.2 —
from another health facility — 3.9 —
agnosis
32.0 37.8 0.003
20.0 22.2 0.91
11.9 14.4 0.055
11.0 4.8 0.17
25.0 20.7 0.024
ic shock 51.8 49.4 0.38
ourse
ssor use† 3.8 3.7 —
e 41.7 31.0 0.13
on 15.3 21.3 0.006
inistration† 4.7 6.8 —
ansplant† 3.8 3.5 —
ent device† 5.2 8.8 —
f comorbidities
16.6 7.5 0.002
25.7 16.6 0.004
27.2 20.5 0.017
30.5 55.5 0.001
ties
nsion 38.4 51.3 0.003
d electrolyte disorders 28.0 41.6 0.002
pathy 24.6 28.2 0.07
s, uncomplicated 18.2 28.4 <0.001
ilure 11.5 24.0 <0.001
cy anemias 10.2 18.8 0.012
pulmonary disease 13.0 17.0 0.23
ral vascular disorders 7.9 16.1 0.004
† 5.7 10.4 —
loss† 5.5 10.6 —
roidism† 4.1 6.8 —
6.1 7.3 —
%. *Data not available before 2008. †Relative standard error exceeded validity
>1 year.
ute myocardial infarction; CAD ¼ coronary atherosclerosis and other heart disease;
estive heart failure; CPR ¼ cardiopulmonary resuscitation; HVD¼ heart valve disorder;
a-aortic balloon pump.Approximately two-thirds of patients were male and
white. In 2008 to 2011, approximately one-half of
patients were $65 years of age. Large urban teaching
hospitals were the predominant setting.
HOSPITAL COURSE AND DISEASE CHARACTERISTICS.
Acute myocardial infarction (AMI) was the most
common primary diagnosis (Table 2, Online Table 3),
and this predominance increased linearly over time
(p for trend ¼ 0.003), whereas other miscellaneous
diagnoses (Online Table 4) made up a declining
proportion of patients (p for trend ¼ 0.024). Approx-
imately one-half of all patients carried a diagnosis of
cardiogenic shock. There was an increase in the pro-
portion of patients with $3 Elixhauser comorbidities
over time (p for trend ¼ 0.001).
LENGTH OF STAY AND DISPOSITION. The mean
duration of stay for congestive heart failure (CHF)
decreased substantially over time (p for trend ¼
0.002) (Table 3). Trends in length of stay for AMI and
coronary artery disease (CAD) did not reach statistical
signiﬁcance. The proportion of patients discharged
home increased over time (p for trend ¼ 0.001). ThisTABLE 3 Trends in Short-Term Mechanical Circulatory
Support Outcomes
Outcome 2004–2007 2008–2011 p Value
Length of stay, days
AMI 18.5  27.3 14.3  19.5 0.09
CAD 10.3  10.4 7.2  10.4 0.06
CHF 58.7  65.5 32.3  35.9 0.002
HVD 11.6  12.7 17.2  22.4 0.44
Other 25.4  41.2 25.6  31.0 0.81
Disposition
Routine (home or self-care) 31.7 47.5 0.001
Home health care 23.0 18.4 0.22
Transfer* 45.3 34.1 0.019
Mortality 41.1 33.4 0.027
AMI 41.4 33.5 0.09
CAD† 37.1 15.4 —
CHF 29.6 34.2 0.54
HVD† 43.3 55.3 —
Other 48.2 46.8 0.17
Mortality with cardiogenic shock 51.6 43.1 0.012
Cost $150,187 $116,858 0.011
AMI $142,176 $97,134 0.015
CAD $120,699 $66,277 0.015
CHF $217,144 $190,612 0.010
HVD $143,606 $133,733 0.82
Other $157,726 $162,811 0.86
Cost with cardiogenic shock $171,509 $146,942 0.034
Values are mean  SD, %, or mean. *Includes short-term hospital, skilled nursing
facility, or intermediate care. †Relative standard error exceeded validity threshold
in >1 year.
Abbreviations as in Table 2.
TABLE 4 Management by Indication for Hospital Stay From
2008 to 2011
AMI CAD CHF HVD Other
Cardiogenic shock 59.5 18.6 56.5 56.0 57.6
Hospital course
Vasopressor use 4.2 1.1 3.7 4.4 5.2
IABP use 39.9 17.4 26.8 51.2 27.7
Intubation 24.3 7.2 27.0 24.6 26.1
CPR administration 7.4 2.2 7.3 8.6 9.8
Permanent device 5.9 1.5 24.8 4.3 11.9
Disposition
Routine 39.7 70.7 37.4 19.4 40.2
Home health care 18.7 11.3 26.8 25.6 20.8
Transfer* 41.6 18.0 35.8 55.0 39.0
Mortality rate 33.5 15.4 34.2 55.3 46.8
Values are %. *Includes short-term hospital, skilled nursing facility, or interme-
diate care.
Abbreviations as in Table 2.
TABLE 5 Multivariable Analysis of Mortality
Odds
Ratio
Lower
95% CI
Upper
95% CI p Value
Age, yrs
18–34 Ref
35–49 1.41 0.85 2.33 0.19
50–64 2.13 1.33 3.41 0.002
65–79 2.41 1.49 3.88 <0.001
$80 1.51 0.85 2.70 0.16
Female 1.44 1.17 1.79 0.001
Hospital characteristics
Teaching hospital* 1.13 0.87 1.47 0.37
Urban location 1.02 0.57 1.84 0.94
Year
2004 Ref
2005 0.30 0.16 0.54 <0.001
2006 0.70 0.39 1.25 0.23
2007 0.43 0.23 0.79 0.007
2008 0.43 0.26 0.71 0.001
2009 0.31 0.19 0.51 <0.001
2010 0.36 0.22 0.58 <0.001
2011 0.30 0.19 0.48 <0.001
Primary diagnosis
AMI Ref
CAD 0.64 0.47 0.88 0.005
CHF 0.92 0.67 1.27 0.61
HVD 1.49 0.98 2.28 0.07
Other 1.56 1.19 2.05 0.001
Cardiogenic shock 1.42 1.14 1.77 0.002
Before heart assist†
CPR administration 3.50 2.20 5.57 <0.001
IABP use 2.00 1.58 2.52 <0.001
Intubation 1.71 1.27 2.30 <0.001
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1411increase was accompanied by a concomitant decline
in transfers to other facilities (p for trend ¼ 0.019). In
2008 to 2011, patients with AMI, CHF, or other
miscellaneous diagnoses were discharged home in
approximately 40% of cases, compared with 70.7%
of those with CAD (Table 4). Patients with CAD also
had the lowest incidence of cardiogenic shock of
all groups.
MORTALITY. As illustrated in Figure 2, mortality rates
of short-term MCS recipients have decreased over70
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FIGURE 2 Mortality Rate Associated With Short-Term
Mechanical Circulatory Support (2004 to 2011)
A trend toward decrease in mortality was observed over time for
recipients of short-term circulatory assist devices. CI ¼ conﬁ-
dence interval.
Vasopressor use 1.39 0.75 2.58 0.30
Comorbidities
Coagulopathy 2.35 1.88 2.94 <0.001
Fluid and electrolyte disorders 1.82 1.47 2.25 <0.001
Deﬁciency anemias 0.44 0.33 0.59 <0.001
CHF 1.38 0.96 1.99 0.08
Diabetes, uncomplicated 0.81 0.64 1.03 0.08
*As classiﬁed in the American Heart Association Annual Survey of Hospitals. †Performed or
administered up to 7 days before short-term mechanical circulatory support.
CI ¼ conﬁdence interval; Ref ¼ reference; other abbreviations as in Table 2.time (p for trend ¼ 0.027) (Table 5). This trend was
also observed in the subset of patients with cardio-
genic shock (p for trend ¼ 0.012). Detailed outcome
data for this subgroup are presented in Online Table 1.
Patients 65 to 79 years of age had the highest odds of
mortality. Comorbidities conveying the greatest risk
were coagulopathies and ﬂuid and electrolyte disor-
ders. Other predictors of death included a diagnosis
of cardiogenic shock and use of IABP or cardiopul-
monary resuscitation before short-term MCS. After
adjusting for all other variables, later calendar years
remained predictive of lower mortality.
TABLE 6 Multivariable Analysis of Total Hospital Costs
Change in Cost (%) p Value
Age, yrs
18–34 Ref
35–49 14.4 0.007
50–64 16.3 0.001
65–79 22.0 <0.001
$80 28.5 <0.001
Female 2.1 0.35
Primary payer
Medicare Ref
Medicaid 2.3 0.58
Private insurer 7.9 0.015
Other 0.4 0.93
Median household income
0–25th percentile Ref
26th–50th percentile 0.1 0.97
51st–75th percentile 4.9 0.14
76th–100th percentile 2.9 0.39
Hospital characteristics
Teaching status 4.7 0.31
Urban location 9.4 0.41
Year
2004 Ref
2005 5.9 0.48
2006 0.3 0.97
2007 12.1 0.11
2008 2.7 0.71
2009 6.4 0.34
2010 8.1 0.23
2011 16.4 0.012
Primary diagnosis
AMI Ref
CAD 9.7 0.002
CHF 8.7 0.021
HVD 24.6 <0.001
Other 12.1 <0.001
Length of stay, per 20% increase 8.4 <0.001
Died during hospital stay 28.5 <0.001
Hospital course
Use of IABP 25.2 <0.001
Intubation 5.8 0.027
Vasopressor use 10.2 0.07
CPR administration 3.4 0.42
Comorbidities
Coagulopathy 17.7 <0.001
Weight loss 12.7 0.002
Hypertension 5.1 0.022
Fluid and electrolyte disorders 3.7 0.13
Chronic pulmonary disease 3.3 0.23
Hypothyroidism 4.4 0.29
CHF 1.7 0.70
Abbreviations as in Table 2.
Stretch et al. J A C C V O L . 6 4 , N O . 1 4 , 2 0 1 4
Short-Term Mechanical Circulatory Support O C T O B E R 7 , 2 0 1 4 : 1 4 0 7 – 1 5
1412HOSPITAL COSTS. The mean cost of hospital stays
declined from 2004 to 2011 (p for trend ¼ 0.011)
(Table 6). Stratifying by diagnosis, costs declined over
time for all groups except patients with heart valvedisorders and other miscellaneous diagnoses. A pa-
tient’s age was found to have a strong inverse corre-
lation with hospital costs. IABP use and in-hospital
death were associated with cost increases of 25.2%
(p < 0.001) and 28.5% (p < 0.001), respectively.
DISCUSSION
These national data demonstrate that use of short-
term MCS increased rapidly between 2007 and 2011,
accompanied by declining rates of in-hospital mor-
tality. Concomitant reductions in hospital costs were
observed during this period.
WHORECEIVES SHORT-TERMMECHANICAL CIRCULATORY
SUPPORT? Recipients of short-term MCS have histor-
ically been patients with cardiogenic shock or circu-
latory collapse who were considered eligible for
transplant or LVAD. Accordingly, delivery of short-
term MCS most often took place in transplant or
LVAD centers and included surgically implanted
temporary devices. Providers were primarily cardiac
surgeons experienced in transplant and LVAD pro-
cedures. Operations to implant these devices are
usually associated with signiﬁcant morbidity; the
mortality of these patients has remained similar
over time.
The availability of percutaneous devices pro-
foundly changed the ﬁeld of short-term MCS. The
results of this study illustrate a paradigm shift char-
acterized by increased use of short-term MCS in an
anticipatory or prophylactic fashion (e.g., during
high-risk PCI and ablation procedures carrying a
likelihood of impaired cardiac output), as opposed to
after the onset of circulatory compromise (Central
Illustration). The most striking demonstration of
this is the large number of patients with a primary
diagnosis of CAD who receive short-term MCS.
This change in the use of short-term MCS, particularly
the evolution of a “nonshock” group of patients, has
had a profound inﬂuence on aggregate outcomes.
MORTALITY. Efforts to reduce the mortality rate of
cardiogenic shock have had limited success. The
SHOCK (Should We Emergently Revascularize
Occluded Coronaries for Cardiogenic Shock) trial
demonstrated that early revascularization in car-
diogenic shock secondary to AMI improves 6- and
12-month survival but does not reduce 30-day mor-
tality (11). The IABP-SHOCK II (Intra-aortic Balloon
Pump in Cardiogenic Shock II) trial revealed no effect
of IABP on 30-day or 12-month survival (3,12). Indeed,
cardiogenic shock in AMI continues to carry an esti-
mated mortality rate of at least 40% to 50% (13,14).
Those patients receiving short-term MCS are among
the most severely ill.
Patient with 
Acute myocardial infarction (AMI), 
Congestive heart failure (CHF), or
Coronary artery disease and other heart disease (CAD)
Organ dysfunction 
has already
occurred
Most MCS
implanted surgically 
(primarily by cardiac surgeons)
Longer hospital 
stay post-surgery
Higher
mortality
Higher 
hospital costs
MCS instituted after
circulatory collapse
(reactive)
Limited or no
 percutaneous MCS
devices available
MCS instituted before
circulatory collapse
(anticipatory)
Percutaneous MCS
devices more
readily available
Avoidance
of organ
dysfunction 
MCS increasingly
implemented without need 
for surgical consultation
Shorter hospital stay 
and higher rate of
home discharges
Lower
mortality
Reduced
hospital costs
PRE-2007 POST-2007
CENTRAL ILLUSTRATION A Paradigm Shift in the Use of Short-Term MCS
Greater availability of percutaneous mechanical circulatory support (MCS) devices, alongside burgeoning expertise in their use among inter-
ventional cardiologists, has resulted in a fundamental change in the approach to patients at risk of acute circulatory collapse.
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1413We identiﬁed high mortality in short-term MCS
recipients with AMI or valvular heart disease but low
mortality among patients with CAD. This difference
is consistent with their respective prevalence of
cardiogenic shock. The growing number of patients
with CAD undergoing percutaneous MCS-assisted
PCI resulted in a decline in overall MCS mortality
over time.
Early identiﬁcation of impending circulatory
collapse coupled with rapid implementation of MCS
may contribute to mortality reductions (15). Newer
MCS devices have reduced the time between decision
and implementation compared with earlier pulsatile
devices that required expertise restricted to centers
with heart transplant or LVAD programs. Guide-
lines need to be developed to help enable early
identiﬁcation of patients for whom IABP is likely to
be insufﬁcient.
UTILIZATION. The observed growth in MCS use likely
results from a reduced treatment threshold. The shift
from predominantly surgical to percutaneous device
delivery has minimized procedural invasiveness and
enhanced ease of delivery. It also has expanded
availability because devices can be implanted in
the catheterization laboratory without the needfor surgical consultation. Ongoing technologic
advances continue to increase the absolute additional
output (l/min) achievable and help to obviate esca-
lation to surgically implanted devices.
QUALITY OF LIFE AND COST. The proportion of pa-
tients discharged home, without need for home
health care, increased over time. Furthermore, the
fraction of patients receiving permanent heart-assist
devices during their hospital stay increased. From
2008 to 2011, 24.8% of the patients with a primary
diagnosis of CHF received permanent devices, which
have been shown to confer both a survival beneﬁt and
an improved quality of life (16).
These improved outcomes have been achieved in
the context of declining hospital costs. Shorter dura-
tions of stay are likely a major factor driving this
decline. The reduced proportion of patients dis-
charged to other facilities suggests these shorter stays
reﬂect more rapid recoveries rather than increased
use of rehabilitation facilities. Implantation of per-
manent devices and heart transplants are associated
with higher hospital costs and lengths of stay.
UNEXPECTED FINDINGS. A somewhat surprising
ﬁnding of our study was the 25.2% increase in the cost
of hospital stay associated with IABP use. One
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Percutaneous heart-assist devices are increasingly
used to prevent circulatory compromise in patients
at risk of acute hemodynamic decompensation.
TRANSLATIONAL OUTLOOK: Future advances
in percutaneous mechanical circulatory assist tech-
nology should address the need for bedside deploy-
ment and reduced levels of hemolysis that currently
limit the duration of support.
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1414possible explanation is that IABP use is associated
with a delay in instituting more aggressive forms of
circulatory support in patients who require it. Such
delays could escalate the severity of cardiogenic
shock and ultimately increase the intensity and cost
of the care required by those patients.
LIMITATIONS OF PERCUTANEOUS SHORT-TERM
MECHANICAL CIRCULATORY SUPPORT DEVICES.
The technology of short-term MCS continues to
evolve. Some devices may be insufﬁcient to augment
cardiac output, whereas others need specialized skills
rare among even skilled interventional cardiologists.
The amount of myocardial support required by pa-
tients in cardiogenic shock is subject to rapid ﬂuctu-
ation. However, the ability to escalate the degree of
cardiac assistance provided by current-generation
percutaneous devices remains limited. Prompt and
repeated assessments to identify cannula positions,
malfunctions, and changes in ﬂow as a result of vol-
ume status are paramount to patients’ survival and
reduction of adverse events.
Perhaps the most crucial aspects of management
are assessments for signs of recovery and for sub-
sequent withdrawal of short-term MCS. Understand-
ing that extended support may be needed before
adequate recovery can occur is critical to manage-
ment and is a major limitation of prior randomized
trials (17–19).
STUDY LIMITATIONS. This study has several limita-
tions inherent to a retrospective analysis. First, the
use of ICD-9-CM codes to identify short-term MCS
procedures did not allow an analysis of outcomes for
individual devices. In addition, a substantial propor-
tion of the study population (21.6%) was assigned a
miscellaneous indication for hospital stay.
In terms of mortality, it is difﬁcult to differentiate
and estimate the impact of short-term MCS evolution
from other concurrent changes during the study
period, including efforts to reduce door-to-balloon
times and length of inpatient stays. Length of stay
and home healthcare requirements were higher in
patients with CHF, although the higher rate ofpermanent device implantation in these patients may
be a confounder. Finally, our analysis was limited to
hospital costs. Increased use of permanent devices
will confer downstream costs to the healthcare sys-
tem, whereas reduced need for home health care
and intermediate facilities at discharge will achieve
cost savings.
CONCLUSIONS
Short-term MCS therapy has witnessed rapid growth
since 2007, with concomitant reductions in both
mortality rates and hospital costs. Systematic and
longitudinal collection of data pertaining to short-
term MCS therapy is warranted to ensure improved
outcomes in the future.
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